Heat Biologics Stock Notches Scorching RS Rating

On Wednesday, Heat Biologics (HTBX) got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 96. The high RS Rating makes Heat Biologics stock one for your market rally watchlist.


As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD’s proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price performance over the trailing 52 weeks holds up against all the other stocks in our database.

History shows that the market’s biggest winners often have an 80 or higher RS Rating at the beginning of a new run.

See How IBD Helps You Make More Money In Stocks

Is Heat Biologics Stock A Buy?

While Heat Biologics stock is not near a proper buying range right now, see if it manages to form and break out of a proper chart pattern.

Top- and bottom-line growth moved higher in the Morrisville, N.C.-based biotech’s most recent quarter. Earnings were up 62%, compared to flat in the prior report. Revenue increased from 74% to 8,400%.

Heat Biologics stock holds the No. 69 rank among its peers in the Medical-Biomed/Biotech industry group. Emergent BioSolutions (EBS), Horizon Pharma (HZNP) and Ligand Pharmaceuticals (LGND) are among the top five highly rated stocks within the group.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button